TCR2 Therapeutics Inc (NASDAQ:TCRR)
| 1.49 Delayed Data As of Mar 24 |  +0.07 / +4.93%Today’s Change | 0.82 Today|||52-Week Range 3.88 | +49.18% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $57.7M |
Company Description
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.
Contact Information
TCR2 Therapeutics, Inc. 100 Binney Street Cambridge Massachusetts 02142 |
Employees
Shareholders
| Mutual fund holders | 9.95% |
| Other institutional | 27.31% |
| Individual stakeholders | 10.17% |
Top Executives
| Garry E. Menzel | President, Chief Executive Officer & Director |
| Peter Olagunju | Chief Operating Officer |
| Eric M. Sullivan | Chief Financial Officer |
| Alfonso Quintás-Cardama | Chief Medical Officer |
| Praveen Malhotra | Vice President-Information Technology |
